Peptide-based covalent inhibitors of MALT1 paracaspase.

Bioorg Med Chem Lett

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Ave, Boston, MA 02115, USA. Electronic address:

Published: June 2019

Potent and selective substrate-based covalent inhibitors of MALT1 protease were developed from the tetrapeptide tool compound Z-VRPR-fmk. To improve cell permeability, we replaced one arginine residue. We further optimized a series of tripeptides and identified compounds that were potent in both a GloSensor reporter assay measuring cellular MALT1 protease activity, and an OCI-Ly3 cell proliferation assay. Example compounds showed good overall selectivity towards cysteine proteases, and one compound was selected for further profiling in ABL-DLBCL cells and xenograft efficacy models.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2019.03.046DOI Listing

Publication Analysis

Top Keywords

covalent inhibitors
8
inhibitors malt1
8
malt1 protease
8
peptide-based covalent
4
malt1 paracaspase
4
paracaspase potent
4
potent selective
4
selective substrate-based
4
substrate-based covalent
4
protease developed
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!